ReviewFrontiers in cell and developmental biology2020
The Application of MSCs-Derived Extracellular Vesicles in Bone Disorders: Novel Cell-Free Therapeutic Strategy.
Review in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Pro-tumorigenic effects and therapeutic implications of mesenchymal stem cell-derived exosomes under hypoxic conditions: a systematic review.Discover oncology · 2026Review
- Review
- Extracellular vesicles: essential agents in critical bone defect repair and therapeutic enhancement.Molecular biology reports · 2025Review
- Mesenchymal Stem Cell-Derived Extracellular Vesicles in Bone-Related Diseases: Intercellular Communication Messengers and Therapeutic Engineering Protagonists.International journal of nanomedicine · 2024Review
- Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis.Frontiers in immunology · 2024Review
- Therapeutic potential of mesenchymal stem cell-derived exosomes in skeletal diseases.Frontiers in molecular biosciences · 2024Review
- Bone Healing Gone Wrong: Pathological Fracture Healing and Non-Unions-Overview of Basic and Clinical Aspects and Systematic Review of Risk Factors.Bioengineering (Basel, Switzerland) · 2023Review
- Senescence induces fundamental changes in the secretome of mesenchymal stromal cells (MSCs): implications for the therapeutic use of MSCs and their derivates.Frontiers in bioengineering and biotechnology · 2023Review
- Extracellular vesicles in osteoarthritis of peripheral joint and temporomandibular joint.Frontiers in endocrinology · 2023Review
- Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy.Cancer gene therapy · 2022Review
- A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis.Bioactive materials · 2022Article
- Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Osteoporosis via MicroRNA-27a-Induced Inhibition of DKK2-Mediated Wnt/β-Catenin Pathway.Inflammation · 2022Article
- Educating EVs to Improve Bone Regeneration: Getting Closer to the Clinic.International journal of molecular sciences · 2022Review
- Extracellular Vesicles in Bone Homeostasis: Emerging Mediators of Osteoimmune Interactions and Promising Therapeutic Targets.International journal of biological sciences · 2022Review
- Immune response following traumatic spinal cord injury: Pathophysiology and therapies.Frontiers in immunology · 2022Review
- Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review.Biomaterials translational · 2022Review
- Research Progress of Exosomes in Bone Diseases: Mechanism, Diagnosis and Therapy.Frontiers in bioengineering and biotechnology · 2022Review
- miR-125a-5p-abundant exosomes derived from mesenchymal stem cells suppress chondrocyte degeneration via targeting E2F2 in traumatic osteoarthritis.Bioengineered · 2021Article
- Osteoclastic effects of mBMMSCs under compressive pressure during orthodontic tooth movement.Stem cell research & therapy · 2021Article
- Exosome-Encapsulated microRNA-127-3p Released from Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Osteoarthritis Through Regulating CDH11-Mediated Wnt/β-Catenin Pathway.Journal of pain research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is crucial for supporting the body, protecting other organs, providing minerals, and secreting hormone to regulate other organ's function. Bone disorders result in pain and disability, severely affecting human health, reducing the quality of life and increasing costs to society. With the rapid increase in the aging population worldwide, bone disorders have become one major disease. As a result, efficacious therapies of bone disorders have become the focus of attention worldwide. Mesenchymal stem cells (MSCs) have been widely explored as a new therapeutic method for numerous diseases. Recent evidence suggests that the therapeutic effects of MSCs are mainly mediated by their extracellular vesicles (EV). MSCs-derived extracellular vesicles (MSCs-EV) is indicated as a novel cell-free alternative to cell therapy with MSCs in regenerative medicine. Here, we review the current knowledge of EV and highlight the application studies of MSCs-EV in bone disorders by focusing on osteoarthritis (OA), rheumatoid arthritis (RA), osteoporosis (OP), and bone fracture. Moreover, we discuss the key issues and perspectives of MSCs-EV as a clinical therapeutic strategy for bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.